News
OCS
7.58
+1.07%
0.08
Weekly Report: what happened at OCS last week (1102-1106)?
Weekly Report · 4d ago
Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Denali Therapeutics (DNLI) and Oculis Holding (OCS)
TipRanks · 11/04 20:40
Oculis Holding Is Maintained at Buy by Guggenheim
Dow Jones · 11/04 15:04
Oculis Holding Price Target Cut to $40.00/Share From $45.00 by Guggenheim
Dow Jones · 11/04 15:04
Guggenheim Maintains Buy on Oculis Holding, Lowers Price Target to $40
Benzinga · 11/04 14:54
Guggenheim Remains a Buy on Oculis Holding (OCS)
TipRanks · 11/04 13:55
Oculis Q3 Loss Widens; PREDICT-1 Dry Eye Data Due Around Year-End
NASDAQ · 11/04 06:39
Oculis Holding AG Reports Q3 2026 Financial Results and Clinical Pipeline Updates
NASDAQ · 11/04 04:18
Oculis Holding GAAP EPS of -0.30 CHF
Seeking Alpha · 11/03 22:27
Oculis Holding Reports Nine-Month Results, Renews $125 Million ATM Program
TipRanks · 11/03 22:07
Oculis expects cash, cash equivalents to provide cash runway into 2H of 2029
TipRanks · 11/03 21:45
Oculis Holding Q3 EPS $(0.37) Beats $(0.49) Estimate, Sales $8.619K Miss $290.000K Estimate
Benzinga · 11/03 21:08
Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
NASDAQ · 11/02 14:00
Weekly Report: what happened at OCS last week (1026-1030)?
Weekly Report · 11/02 10:12
Weekly Report: what happened at OCS last week (1019-1023)?
Weekly Report · 10/26 10:11
Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win
NASDAQ · 10/23 14:53
Oculis Holding Price Target Maintained With a $39.00/Share by HC Wainwright & Co.
Dow Jones · 10/23 10:42
HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target
Benzinga · 10/23 10:32
Oculis reports Phase 2 data supporting Privosegtor in optic neuritis
TipRanks · 10/22 13:06
Oculis Reports New Phase 2 Privosegtor Biomarker Findings In Optic Neuritis
NASDAQ · 10/22 07:13
More
Webull provides a variety of real-time OCS stock news. You can receive the latest news about Oculis Holding through multiple platforms. This information may help you make smarter investment decisions.
About OCS
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.